Edan Instruments Inc (300206) - Net Assets
Based on the latest financial reports, Edan Instruments Inc (300206) has net assets worth CN¥2.14 Billion CNY (≈ $313.85 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.51 Billion ≈ $366.77 Million USD) and total liabilities (CN¥361.67 Million ≈ $52.92 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 300206 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.14 Billion |
| % of Total Assets | 85.57% |
| Annual Growth Rate | 19.3% |
| 5-Year Change | 10.73% |
| 10-Year Change | 65.09% |
| Growth Volatility | 101.35 |
Edan Instruments Inc - Net Assets Trend (2008–2024)
This chart illustrates how Edan Instruments Inc's net assets have evolved over time, based on quarterly financial data. See Edan Instruments Inc (300206) defensive interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Edan Instruments Inc (2008–2024)
The table below shows the annual net assets of Edan Instruments Inc from 2008 to 2024. For live valuation and market cap data, see Edan Instruments Inc (300206) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.01 Billion ≈ $293.80 Million |
+2.23% |
| 2023-12-31 | CN¥1.96 Billion ≈ $287.38 Million |
+6.08% |
| 2022-12-31 | CN¥1.85 Billion ≈ $270.91 Million |
+6.90% |
| 2021-12-31 | CN¥1.73 Billion ≈ $253.43 Million |
-4.49% |
| 2020-12-31 | CN¥1.81 Billion ≈ $265.33 Million |
+39.63% |
| 2019-12-31 | CN¥1.30 Billion ≈ $190.03 Million |
+3.25% |
| 2018-12-31 | CN¥1.26 Billion ≈ $184.06 Million |
+0.49% |
| 2017-12-31 | CN¥1.25 Billion ≈ $183.16 Million |
+2.12% |
| 2016-12-31 | CN¥1.23 Billion ≈ $179.36 Million |
+0.79% |
| 2015-12-31 | CN¥1.22 Billion ≈ $177.96 Million |
+4.61% |
| 2014-12-31 | CN¥1.16 Billion ≈ $170.12 Million |
-1.46% |
| 2013-12-31 | CN¥1.18 Billion ≈ $172.64 Million |
+0.29% |
| 2012-12-31 | CN¥1.18 Billion ≈ $172.14 Million |
+3.30% |
| 2011-12-31 | CN¥1.14 Billion ≈ $166.63 Million |
+423.64% |
| 2010-12-31 | CN¥217.47 Million ≈ $31.82 Million |
+42.89% |
| 2009-12-31 | CN¥152.19 Million ≈ $22.27 Million |
+27.60% |
| 2008-12-31 | CN¥119.27 Million ≈ $17.45 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Edan Instruments Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1935.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥896.34 Million | 44.63% |
| Common Stock | CN¥581.72 Million | 28.96% |
| Other Comprehensive Income | CN¥265.49 Million | 13.22% |
| Other Components | CN¥264.87 Million | 13.19% |
| Total Equity | CN¥2.01 Billion | 100.00% |
Edan Instruments Inc Competitors by Market Cap
The table below lists competitors of Edan Instruments Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS
|
$1.12 Billion |
|
Hagar hf
IC:HAGA
|
$1.12 Billion |
|
EST Tools Co Ltd
SHE:300488
|
$1.12 Billion |
|
Kestra Medical Technologies, Ltd. Common Stock
NASDAQ:KMTS
|
$1.12 Billion |
|
Aktis Oncology, Inc. Common stock
NASDAQ:AKTS
|
$1.12 Billion |
|
Petkim Petrokimya Holding AS
IS:PETKM
|
$1.12 Billion |
|
Orient Semiconductor Electronics Ltd
TW:2329
|
$1.12 Billion |
|
VIEL & Cie société anonyme
PA:VIL
|
$1.12 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Edan Instruments Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,965,276,976 to 2,008,426,242, a change of 43,149,266 (2.2%).
- Net income of 162,109,421 contributed positively to equity growth.
- Dividend payments of 119,990,310 reduced retained earnings.
- Other comprehensive income increased equity by 18,422,206.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥162.11 Million | +8.07% |
| Dividends Paid | CN¥119.99 Million | -5.97% |
| Other Comprehensive Income | CN¥18.42 Million | +0.92% |
| Other Changes | CN¥-17.39 Million | -0.87% |
| Total Change | CN¥- | 2.20% |
Book Value vs Market Value Analysis
This analysis compares Edan Instruments Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.81x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 64.48x to 3.81x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | CN¥0.21 | CN¥13.22 | x |
| 2009-12-31 | CN¥0.35 | CN¥13.22 | x |
| 2010-12-31 | CN¥0.49 | CN¥13.22 | x |
| 2011-12-31 | CN¥2.14 | CN¥13.22 | x |
| 2012-12-31 | CN¥1.98 | CN¥13.22 | x |
| 2013-12-31 | CN¥2.03 | CN¥13.22 | x |
| 2014-12-31 | CN¥2.08 | CN¥13.22 | x |
| 2015-12-31 | CN¥2.03 | CN¥13.22 | x |
| 2016-12-31 | CN¥2.05 | CN¥13.22 | x |
| 2017-12-31 | CN¥2.11 | CN¥13.22 | x |
| 2018-12-31 | CN¥2.13 | CN¥13.22 | x |
| 2019-12-31 | CN¥2.21 | CN¥13.22 | x |
| 2020-12-31 | CN¥3.12 | CN¥13.22 | x |
| 2021-12-31 | CN¥3.00 | CN¥13.22 | x |
| 2022-12-31 | CN¥3.20 | CN¥13.22 | x |
| 2023-12-31 | CN¥3.39 | CN¥13.22 | x |
| 2024-12-31 | CN¥3.47 | CN¥13.22 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Edan Instruments Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.07%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.84%
- • Asset Turnover: 0.77x
- • Equity Multiplier: 1.19x
- Recent ROE (8.07%) is below the historical average (12.48%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 23.81% | 16.15% | 1.32x | 1.12x | CN¥16.47 Million |
| 2009 | 30.16% | 20.05% | 1.15x | 1.31x | CN¥30.69 Million |
| 2010 | 30.71% | 20.59% | 1.21x | 1.24x | CN¥44.52 Million |
| 2011 | 5.20% | 15.77% | 0.32x | 1.04x | CN¥-54.55 Million |
| 2012 | 4.72% | 14.43% | 0.30x | 1.08x | CN¥-61.83 Million |
| 2013 | 2.95% | 7.63% | 0.36x | 1.08x | CN¥-82.81 Million |
| 2014 | 1.16% | 2.57% | 0.39x | 1.17x | CN¥-102.73 Million |
| 2015 | 8.70% | 18.76% | 0.38x | 1.22x | CN¥-15.39 Million |
| 2016 | 2.19% | 3.78% | 0.48x | 1.22x | CN¥-93.90 Million |
| 2017 | 3.55% | 5.19% | 0.59x | 1.16x | CN¥-79.65 Million |
| 2018 | 7.44% | 9.33% | 0.69x | 1.16x | CN¥-31.91 Million |
| 2019 | 10.21% | 11.60% | 0.76x | 1.16x | CN¥2.76 Million |
| 2020 | 36.07% | 28.17% | 1.03x | 1.25x | CN¥472.06 Million |
| 2021 | 13.36% | 14.14% | 0.80x | 1.18x | CN¥58.15 Million |
| 2022 | 12.57% | 13.37% | 0.78x | 1.21x | CN¥47.64 Million |
| 2023 | 11.26% | 11.42% | 0.88x | 1.13x | CN¥24.77 Million |
| 2024 | 8.07% | 8.84% | 0.77x | 1.19x | CN¥-38.73 Million |
Industry Comparison
This section compares Edan Instruments Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,163,912,367
- Average return on equity (ROE) among peers: 13.63%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Edan Instruments Inc (300206) | CN¥2.14 Billion | 23.81% | 0.17x | $1.12 Billion |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $381.82 Million | 11.22% | 0.17x | $378.59 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $6.16 Billion | 12.22% | 0.29x | $3.73 Billion |
| Double Medical Technology Inc (002901) | $224.61 Million | 43.10% | 0.32x | $2.54 Billion |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $6.02 Billion | 1.24% | 0.10x | $510.38 Million |
| Lepu Medical Tech Beijing (300003) | $1.76 Billion | 16.64% | 0.06x | $3.18 Billion |
| INKON Life Technology Co Ltd (300143) | $1.81 Billion | -20.17% | 0.37x | $764.39 Million |
| Guangdong Biolight Meditech Co Ltd (300246) | $377.93 Million | 9.66% | 0.15x | $693.09 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $105.32 Million | 39.32% | 0.45x | $487.98 Million |
| Sinocare Inc (300298) | $2.65 Billion | 9.46% | 0.24x | $1.20 Billion |
About Edan Instruments Inc
Edan Instruments, Inc. engages in the research, development, manufacture, and service of medical electronic equipment and in vitro diagnostic products in China and internationally. The company offers ECG products, including resting ECG, stress test, holter, wireless solution, and ECG workstation products; patient monitoring systems, such as modular and compact patient monitor, vital signs, and te… Read more